{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:54:11Z","timestamp":1776261251402,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1080\/14653240310001028","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T18:42:16Z","timestamp":1062096136000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy"],"prefix":"10.1016","volume":"5","author":[{"given":"M.C.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.J.N.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Raubitschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1080\/14653240310001028_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1080\/14653240310001028_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1080\/14653240310001028_bib3","first-page":"1763","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology (Huntinff)"},{"key":"10.1080\/14653240310001028_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3816\/CLM.2000.n.015","article-title":"Rituximab therapy of B-cell neo plasms","volume":"l","author":"Petryk","year":"2000","journal-title":"Clin lymph"},{"key":"10.1080\/14653240310001028_bib5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose reatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1080\/14653240310001028_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"ongoing and future clinical development","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1080\/14653240310001028_bib7","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1080\/14653240310001028_bib8","first-page":"3281s","article-title":"Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y- labeled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1080\/14653240310001028_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1080\/14653240310001028_bib10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-ce!l non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"issue":"Suppl","key":"10.1080\/14653240310001028_bib11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.10307","article-title":"High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study","volume":"94","author":"Behr","year":"2002","journal-title":"Cancer"},{"key":"10.1080\/14653240310001028_bib12","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1080\/14653240310001028_bib13","first-page":"892","article-title":"Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia and lymphoma","author":"Champlin","year":"1999"},{"key":"10.1080\/14653240310001028_bib14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood.V91.6.2197","article-title":"Cytotoxic T-lympho-cyte-defined human minor histocompatibility antigens with a restricted tissue distribution","volume":"91","author":"Warren","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001028_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/smim.1997.0064","article-title":"CTL effector functions","volume":"9","author":"Henkart","year":"1997","journal-title":"Semin Immunol"},{"key":"10.1080\/14653240310001028_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0952-7915(96)80078-1","article-title":"Human tumor antigens recognized by T cells","volume":"8","author":"Robbins","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1080\/14653240310001028_bib17","first-page":"125","article-title":"Identification of genes coding for tumor antigens recognized by cytolytic T lympho cytes","volume":"12","author":"De Plaen","year":"1997","journal-title":"Immunol Methods"},{"key":"10.1080\/14653240310001028_bib18","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.4049\/jimmunol.157.9.4079","article-title":"Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus","volume":"157","author":"Yee","year":"1996","journal-title":"J Immunol"},{"key":"10.1080\/14653240310001028_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/bbmt.1998.v4.pm9763110","article-title":"CD20 is a molecular target for scFvFczeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy","volume":"4","author":"Jensen","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1080\/14653240310001028_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/BF02621085","article-title":"Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A","volume":"22","author":"Pelloquin","year":"1986","journal-title":"In Vitro Cell Dev Biol"},{"key":"10.1080\/14653240310001028_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/mthe.1999.0012","article-title":"Human T lymphocyte genetic modification with naked DNA","volume":"l","author":"Jensen","year":"2000","journal-title":"Mol Ther"},{"key":"10.1080\/14653240310001028_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1080\/14653240310001028_bib23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1089\/10430340050015536","article-title":"Human gene marker\/therapy clinical protocols","volume":"11","author":"Rosenberg","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1080\/14653240310001028_bib24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1080\/14653240310001028_bib25","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324903711281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:08:54Z","timestamp":1761430134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324903711281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003]]}},"alternative-id":["S1465324903711281"],"URL":"https:\/\/doi.org\/10.1080\/14653240310001028","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1080\/14653240310001028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}